Ireland· IE-PA-PA23148/006/001
Griseofulvin 500 mg film-coated tablets
A griseofulvin product containing griseofulvin, registered in Ireland by Brown & Burk IR Limited. The same ATC class is registered in 3 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Griseofulvin is registered in 3 of 19 countries.
Countries holding a registration under ATC D01BA01 (griseofulvin), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 2 of them publish a price we can compare per daily dose
Griseofulvin · ATC D01BA01
3 / 19 countries
- Finlandprice
- Ireland
- Norwayprice
The record
At a glance
HPRA (Ireland)- Active substance
- Griseofulvin
- Manufacturer
- Brown & Burk IR Limited
- Country
- Ireland (IE)
- ATC code
- D01BA01
- ATC class
- Griseofulvin
- Defined daily dose
- 0.5 g, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberPA23148/006/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
303 interactions on record for griseofulvin.
Graded by severity as the source publishes them — 21 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Griseofulvin · interactions on record
303 records
- 21 severe
- 262 moderate
- 20 minor
Most severe, free to view
- RanolazineC01EB18severe
- IUP aus Plastik mit GestagenG02BA03severe
- Levonorgestrel and ethinylestradiolG03AA07severe
- Desogestrel and ethinylestradiolG03AA09severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Griseofulvin in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomFulsovin 125mg/5ml oral suspensionKappin Ltd
- United StatesGriseofulvinSigmapharm Laboratories, LLC
- FinlandFulcinAstraZeneca UK Limited
- ItalyFULCIN 125*20 cpr 125 mgSIT LABORATORIO FARMAC. Srl
- NorwayFulcinLaboratorio Farmaceutico S.I.T. Srl
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- Cyprus · Griseofulvin Remedica, Medofulvin
- France · Grisefuline
- United Kingdom (Northern Ireland) · Griseofulvin Brown & Burk Uk, Grisol
- Italy · Fulcin
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b59fbfdd-b1a1-4258-b6f8-a124dcb20abd GET /v1/drugs/b59fbfdd-b1a1-4258-b6f8-a124dcb20abd?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"D01BA",
"D01BA01"
],
"strength": null,
"pa_number": "PA23148/006/001",
"substances": [
"Griseofulvin"
],
"legal_basis": "Generic application (Article 10(1) of Directive No 2001/83/EC)",
"market_info": "Marketed",
"authorised_at": "25/03/2011",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about griseofulvin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.